Announcing the Launch of 3pm AFTERNOON BITES™
SAN ANTONIO--(BUSINESS WIRE)--San Antonio-based 3pm, LLC is proud to announce the launch of 3pm AFTERNOON BITES™, the first-of-its-kind snack in the U.S. to contain postbiotics and their groundbreaking health benefits.
'By integrating postbiotics with plant-based proteins and nutrient-rich ingredients, we've developed a product that not only tastes amazing but also fuels your body in the healthiest way possible.' - Dr. Sylvia Klinger, Author, 3pm Chief Nutrition Advisor
Share
Designed to help overcome the inevitable 3PM slump, 3pm AFTERNOON BITES™ is a delicious, better-for-you snack powered by plants, protein, and IMMUSE® LC-Plasmapostbiotic to deliver a balanced, nourishing boost when you need it most.
3pm AFTERNOON BITES™ is a new type of snack for health-conscious snackers seeking fresh, innovative options. Its quality, plant-based ingredients provide a balanced source of energy to help beat the brain fog and fatigue of the afternoon slump. With each bite, wellness-minded snackers can enjoy a delicious treat that is both nourishing and indulgent—offering the perfect balance of taste, texture, and health benefits.
'We recognized the need for a truly healthy and delicious snack that supports overall well-being and helps boost productivity. With 3pm AFTERNOON BITES™, we've created the first postbiotic-powered snack in the U.S., designed to give you the right kind of energy at the right time,' said Dr. Sylvia Klinger, globally recognized nutrition expert and 3pm's Chief Nutrition Advisor. 'By integrating postbiotics with plant-based proteins and nutrient-rich ingredients, we've developed a product that not only tastes amazing but also fuels your body in the healthiest way possible.'
Postbiotics are bioactive compounds that are gaining recognition for their broad range of science-backed benefits. Studies have shown that postbiotics can provide lasting benefits and among these is year-round immune support to help maintain productivity and performance, making them a smart choice in combating the afternoon slump.
Unlike probiotics, which can be sensitive to temperature and time, postbiotics are stable at room temperature, making them easier to store and more reliable for consumers. This added stability ensures that the health benefits remain consistent and effective from the moment the product is manufactured until it is consumed, offering a level of convenience and reliability that traditional probiotics cannot match.
'We're incredibly excited to bring 3pm AFTERNOON BITES™ to the market and help people make healthier snack choices without sacrificing taste or quality,' said Eduardo Domínguez, 3pm, LLC CEO. 'Whether you're looking to avoid that 3PM crash, help fuel your productivity, or simply enjoy a delicious snack, 3pm AFTERNOON BITES™ is here to support your wellness goals.'
With its unique blend of wholesome ingredients and postbiotics, 3pm AFTERNOON BITES™ is a good source of protein and fiber, and contains low added sugar, fat and sodium. It is poised to disrupt the $53 billion snack industry and offer a new standard for delicious, functional snacks. As of April 2025, find them at select H-E-B stores across Texas. They are available in two tasty varieties - Cranberry/Flaxseed and Dark Chocolate/Almond – and retail starting at $4.98 for the box of five cookies.
About 3pm, LLC
3pm, LLC is a pioneering company committed to promoting holistic wellbeing though engaging content, initiatives, partnerships and innovative better-for-you products like 3pm AFTERNOON BITES™ - and others in development. Learn more about our mission and 3pm AFTERNOON BITES™ at https://3pmbreak.com.
IMMUSE ® is a postbiotic that delivers a new, breakthrough approach to broad range immune support. Its unique mechanism of action, discovered by Kyowa Hakko's parent company Kirin Holdings Co., Ltd., is opening doors for discovering postbiotics concerning immune health. Learn more at https://immusehealth.com/benefits
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
- The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilize a challenging drug target and advance Daewoong Pharmaceutical's drug discovery programs for the generation of small molecule drugs. SEOUL, South Korea, June 11, 2025 /PRNewswire/ -- Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co., Ltd. Daewoong Pharmaceutical gains access to Salipro Biotech's expertise and Salipro® platform for stabilizing challenging membrane proteins (e.g., GPCRs, ion channels, transporters). The collaboration will target a specific membrane protein to aid Daewoong's development of novel small molecule drugs. Under the terms of this agreement, the collaboration will enable Daewoong Pharma to leverage Salipro Biotech´s expertise and proprietary platform to advance their drug discovery efforts in the development of novel therapeutic small molecules against a challenging membrane protein drug target. "We are excited to join forces with Daewoong Pharmaceutical and contribute with our proprietary Salipro® platform to accelerate the development of novel therapeutic drugs for Daewoong Pharmaceutical's pipeline", said Jens Frauenfeld, CEO of Salipro Biotech. "This partnership is particularly significant as it marks our first collaboration with a partner in South Korea, underscoring the global application and versatility of our expertise and platform to make the undruggable druggable." Seongsoo Park, CEO at Daewoong Pharmaceutical stated, "Collaborating with Salipro Biotech and accessing their Salipro® platform aligns with our goal to address complex drug targets. Salipro's expertise in membrane protein stabilization will benefit our research for novel small molecule therapeutics, and we look forward to the results of our joint efforts." About Salipro Biotech ABSalipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, Sweden with a fully owned IP portfolio that covers the Salipro® platform technology for the stabilization of membrane proteins. The majority of drug targets are so-called membrane proteins; however, these targets are inherently unstable and challenging to investigate. The proprietary Salipro® technology stabilizes membrane proteins in their native forms, enabling them to be employed in drug discovery programs for therapeutic antibodies, small molecule drugs and structure-based drug design. To date, Salipro Biotech has signed multiple research collaborations with top-tier pharma and biotech companies. Through in-house and partnered pipelines, Salipro Biotech AB accelerates the discovery of novel drugs. About Daewoong PharmaceuticalDaewoong Pharmaceutical (KRX: established in 1945, is a global pharmaceutical company based in South Korea. The company is committed to the development, manufacturing, and commercialization of pharmaceutical products, with a mission to provide the most beneficial total solutions, including pharmaceuticals and services, which contribute to improving the quality of life of valued consumers. Operating with a keen focus on both domestic and international markets, Daewoong Pharmaceutical specializes in developing treatments for intractable and rare diseases. The company's diverse portfolio encompasses novel drugs, biologics, new products, and C&D, all supported by in-house research and development, open collaboration, and advanced manufacturing facilities. Marking significant achievements in drug development, Daewoong Pharmaceutical has successfully developed novel drugs for GERD, featuring the active ingredient Fexuprazan, and for Type 2 diabetes, with the active ingredient Enavogliflozin, in two consecutive years. The company is currently advancing in the development of First-in-Class Oral Anti-Fibrotic Agent for Idiopathic Pulmonary Fibrosis, utilizing Bersiporocin as a PRS Inhibitor. Notably, Bersiporocin has been designated by the U.S. FDA as an orphan drug and a Fast Track development product. View original content to download multimedia: SOURCE Daewoong Pharmaceutical Co., Ltd.
Yahoo
4 hours ago
- Yahoo
Anti-DEI group targets Geisinger College of Health Sciences over program
SCRANTON — A national anti-DEI group has targeted the Geisinger College of Health Sciences with recent filings of discrimination complaints. Virginia-based Do No Harm purported in news releases in March and June that it filed separate complaints with two federal agencies against the college, citing as discriminatory its federally funded Center of Excellence for Diversity and Inclusion and a summer program that aimed to help students from Black, Hispanic or Native American communities that are underrepresented in the medical field transition into medical school. The Do No Harm discrimination complaints come amid President Donald Trump's efforts to dismantle DEI, or diversity, equity and inclusion, programs in the public and private sectors. Trump issued executive orders in the first week of his second term targeting DEI initiatives. 'Geisinger College of Health Sciences did a thorough review of our programs after the presidential executive orders were issued to ensure compliance. The pre-matriculation program referenced in the (Do No Harm) complaint ended in 2024 and is no longer active,' Geisinger CHS said in a statement. Do No Harm is labeled by the Southern Poverty Law Center as an 'anti-LGBTQ+ hate group.' Critics of the SPLC say it's politically biased and its definition of hate group is overly broad. Do No Harm first filed a complaint with the U.S. Department of Health and Human Services on March 19 against Geisinger CHS, according to a news release posted on the Do No Harm website. A member of Do No Harm then filed a similar complaint June 5 with the U.S. Department of Education, because Geisinger 'did not learn its lesson' from the initial complaint filed with HHS, the advocacy organization announced in another news release. The Times-Tribune could not verify that the complaints were filed with both departments, and whether either agency investigated the allegations or took any actions. The U.S. Department of Health and Human Services and the U.S. Department of Education through separate representatives said they do not confirm the existence of complaints. Do No Harm, established in April 2022, claims it has 17,000 members, including doctors, nurses, physicians and concerned citizens, and cites its mission as safeguarding health care from ideological threats. 'Do No Harm seeks to highlight and counteract divisive trends in medicine, such as 'Diversity, Equity and Inclusion' and youth-focused gender ideology,' the organization's website says. According to the SPLC, Do No Harm in 2024 filed eight lawsuits challenging programs such as scholarships and fellowships for marginalized people. 'The group claims that the practice of nonprofit organizations like the American Association of University Women to provide fellowships to students of color and LGBTQ+ students — groups historically underrepresented in academia and medicine — harms patients by requiring medical schools to accept or fund unqualified candidates. According to the group, the case was dismissed 'after AAUW agreed to drop the racial criteria in the fellowship's selection process,'' the SPLC website says. According to the website of Geisinger College of Health Sciences, it is the research and education arm of the Geisinger health system. Established in 2022, the college unifies the Geisinger Commonwealth School of Medicine, Geisinger School of Nursing, Geisinger School of Graduate Education, graduate medical education, Center for Faculty and Professional Development and more. * Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) * Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) * Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) Show Caption 1 of 3 Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) Expand
Yahoo
5 hours ago
- Yahoo
Anti-DEI group targets Geisinger College of Health Sciences over program
SCRANTON — A national anti-DEI group has targeted the Geisinger College of Health Sciences with recent filings of discrimination complaints. Virginia-based Do No Harm purported in news releases in March and June that it filed separate complaints with two federal agencies against the college, citing as discriminatory its federally funded Center of Excellence for Diversity and Inclusion and a summer program that aimed to help students from Black, Hispanic or Native American communities that are underrepresented in the medical field transition into medical school. The Do No Harm discrimination complaints come amid President Donald Trump's efforts to dismantle DEI, or diversity, equity and inclusion, programs in the public and private sectors. Trump issued executive orders in the first week of his second term targeting DEI initiatives. 'Geisinger College of Health Sciences did a thorough review of our programs after the presidential executive orders were issued to ensure compliance. The pre-matriculation program referenced in the (Do No Harm) complaint ended in 2024 and is no longer active,' Geisinger CHS said in a statement. Do No Harm is labeled by the Southern Poverty Law Center as an 'anti-LGBTQ+ hate group.' Critics of the SPLC say it's politically biased and its definition of hate group is overly broad. Do No Harm first filed a complaint with the U.S. Department of Health and Human Services on March 19 against Geisinger CHS, according to a news release posted on the Do No Harm website. A member of Do No Harm then filed a similar complaint June 5 with the U.S. Department of Education, because Geisinger 'did not learn its lesson' from the initial complaint filed with HHS, the advocacy organization announced in another news release. The Times-Tribune could not verify that the complaints were filed with both departments, and whether either agency investigated the allegations or took any actions. The U.S. Department of Health and Human Services and the U.S. Department of Education through separate representatives said they do not confirm the existence of complaints. Do No Harm, established in April 2022, claims it has 17,000 members, including doctors, nurses, physicians and concerned citizens, and cites its mission as safeguarding health care from ideological threats. 'Do No Harm seeks to highlight and counteract divisive trends in medicine, such as 'Diversity, Equity and Inclusion' and youth-focused gender ideology,' the organization's website says. According to the SPLC, Do No Harm in 2024 filed eight lawsuits challenging programs such as scholarships and fellowships for marginalized people. 'The group claims that the practice of nonprofit organizations like the American Association of University Women to provide fellowships to students of color and LGBTQ+ students — groups historically underrepresented in academia and medicine — harms patients by requiring medical schools to accept or fund unqualified candidates. According to the group, the case was dismissed 'after AAUW agreed to drop the racial criteria in the fellowship's selection process,'' the SPLC website says. According to the website of Geisinger College of Health Sciences, it is the research and education arm of the Geisinger health system. Established in 2022, the college unifies the Geisinger Commonwealth School of Medicine, Geisinger School of Nursing, Geisinger School of Graduate Education, graduate medical education, Center for Faculty and Professional Development and more. * Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) * Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) * Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) Show Caption 1 of 3 Geisinger College of Medicine in Scranton on Monday, June 9, 2025. (REBECCA PARTICKA/STAFF PHOTOGRAPHER) Expand
